The spinout of the University of California, Davis Foods For Health Institute intends the test to be used at the point of care in pediatrician's offices.
The platform, which its developers said is well suited to point-of-care testing, uses fluorescent polymers to distinguish between samples from cases and controls.
Exalenz's systems, the BreathID Hp point-of-care system and the BreathID Hp Lab system, were previously cleared by the FDA for use in detecting H. pylori infection in adults.
Researchers at Cincinnati Children's Hospital have identified markers for earlier detection of the condition, for which patient outcomes hinge on rapid action.
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.
Nearly 8,000 patients participated in a screening study that used a PCR-based detection assay from Becton Dickinson, uncovering a 5 percent carrier rate.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
